UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ Form 10-Q ___________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34899 ___________________________________ Pulse Bioscien ...

Financial Data and Key Metrics Changes - Operating expenses for Q1 2020 were $12 million, up from $10.4 million in the prior year, driven by expansion in operational infrastructure and clinical trial costs [49] - Net loss for Q1 2020 was $11.9 million, compared to $10.1 million in Q1 2019 [51] - Cash and cash equivalents totaled $15.9 million as of March 31, 2020, down from $25.4 million as of December 31, 2019 [51] Business Line Data and Key Metrics Changes - The company reported an increase in general and administrative expenses to $5.6 million from $4.4 million, primarily due to increased personnel [49] - Research and development expenses rose to $6.2 million from $5.8 million, also attributed to increased personnel [50] Market Data and Key Metrics Changes - The COVID-19 pandemic significantly impacted elective procedure volumes, with 92% of surveyed dermatologists reporting a reduction of at least 50% in aesthetic procedures [36] - Despite the downturn, 75% of aesthetic dermatologists indicated they are actively scheduling future procedures, reflecting optimism for a rapid recovery [38] Company Strategy and Development Direction - The company aims for regulatory clearance of the CellFX System in the U.S. and EU, with a goal to submit a 510(k) application by Q3 2020 [21][28] - Plans for commercialization in the EU are underway, with the potential to obtain CE Mark as early as Q1 2021 due to regulatory delays [26][28] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about the company's prospects despite the challenges posed by COVID-19, emphasizing progress on key objectives [7][56] - The company is adapting to remote work and has implemented new workflows to maintain operations without significant disruption [10][11] Other Important Information - The company is pursuing a rights offering to raise up to $30 million, with expected net proceeds of approximately $29.5 million [52] - The rights offering is structured to allow stockholders to purchase units consisting of common stock and warrants, with no expected dilution for those who fully exercise their rights [53][54] Q&A Session Summary - No specific questions or answers were documented in the provided content, as the call concluded without a Q&A segment [60][61]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ Form 10-Q ___________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34899 ___________________________________ Pulse Bioscien ...

Pulse Biosciences (Nasdaq : PLSE) March 2020 Forward-looking statements This presentation and accompanying oral presentation by Pulse Biosciences, Inc., contain estimates and forward-looking statements as of March 3, 2020 including, among others, statements regarding Pulse Biosciences' future business plans, products, commercial applications, clinical trials, regulatory processes and pathways, markets for its technologies, and other future events. You should not place undue reliance on forward-looking state ...

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2019 Earnings Conference Call March 16, 2020 4:30 PM ET Company Participants Philip Taylor - Investor Relations Darrin Uecker - President and Chief Executive Officer Ed Ebbers - Executive Vice President and General Manager, Dermatology Sandy Gardiner - Executive Vice President and Chief Financial Officer Bob Duggan - Chairman Conference Call Participants Sean Kang - H.C. Wainwright Michael Fox - Park City Capital Operator Greetings, welcome to Pulse Biosciences Repor ...

Form 10-K ____________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________ Pulse Biosciences, Inc. (Exact name of registrant as specified in its charter) _________________________ ...

Pulse Biosciences (Nasdaq : PLSE) March 2020 Forward-looking statements This presentation and accompanying oral presentation by Pulse Biosciences, Inc., contain estimates and forward-looking statements as of March 3, 2020 including, among others, statements regarding Pulse Biosciences' future business plans, products, commercial applications, clinical trials, regulatory processes and pathways, markets for its technologies, and other future events. You should not place undue reliance on forward-looking state ...

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q3 2019 Earnings Conference Call November 7, 2019 4:30 PM ET Company Participants Brian Dow - SVP & CFO Darrin Uecker - President & CEO Ed Ebbers - EVP & GM, Dermatology Conference Call Participants Arthur He - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the Pulse Biosciences' Third Quarter 2019 Investor and Analyst Update Conference Call. As a reminder, this conference call is being recorded. I'd now like to turn the conference over to ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34899 ___________________________________ Washington, D.C. 20549 ___________________________________ Form 10-Q ___________________________________ (Mark One) Pulse Bios ...

Pulse Biosciences, Inc(NASDAQ:PLSE) Q2 2019 Earnings Conference Call August 8, 2019 4:30 PM ET Company Participants Brian Dow – Senior Vice President and Chief Financial Officer Darrin Uecker – President and Chief Executive Officer Ed Ebbers – Executive Vice President and General Manager of Dermatology Conference Call Participants Swayampakula Ramakanth – H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the Pulse Biosciences' Second Quarter 2019 Earnings Conference Call. [Operat ...